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Figure 1. A Minimal Bacterial Community
that Establishes a Balance between Pro-
and Anti-inflammatory T Cells in the Gut
Colonization of germ-free mice with ASF promotes
proinflammatory Th17 cell responses, capable of
keeping invading pathogens and opportunistic
infections at bay, and anti-inflammatory Treg cells.
IL-10 produced by diverse cell types, including
Foxp3+ Treg and Foxp3 Tr1 cells, plays an impor-
tant role in limiting Th17 cell responses.
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Previewsdetermine whether Th17 cell-inducing
ASF component(s) also provide some
challenge to the epithelium.
The work of Geuking et al. makes an
important point and elicits many morequestions. The key finding is that complex
host-microbe interactions leading to
establishment of basic regulatory loops
can be reproduced upon colonization
with a small variety of microbes (Figure 1).
Moreover, ASF can induce a Th17 cell
response, albeit a weaker response in
comparison to that elicited by a ‘‘certified’’
inducer of Th17 cells, the SFB. However,
it is still not clear what signals can be
induced by individual members of ASF,
because the monocolonization experi-
ments were unsuccessful. Although not
all members were tested, a single Clos-
tridium species tested notably failed to
associate with the host. It is possible
that it requires other components of ASF
to either provide necessary nutrition or
assist with engraftment by modifying the
host tissue. Further experiments are
needed to determine whether specific
arms of the regulatory and effector mech-
anisms can be separately regulated by
individual ASF members or whether the
consortium as a whole is required.
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In this issue of Immunity, Egen et al. (2011) provide compelling evidence that only a minute fraction of myco-
bacteria-specific T cells present in a granuloma are actively fulfilling effector functions, an observation that
may in fact be a general feature of chronic infections.To receive activation signals and exert
their effector functions, antigen-specific
T cells establish interactions with antigen-
presenting cells (APCs). In secondary
lymphoid organs, naive T cells form con-
tacts with antigen-bearing dendritic cells(DCs), and these interactions have been
extensively studied with the help of two-
photon imaging (Cahalan and Parker,
2008). Long-lived T cell:DC interactions
lasting several hours are often seen dur-
ing this phase, in particular in conditionsof robust and efficient T cell activation
(Bousso, 2008). In contrast, the way that
effector T cells alter their behavior upon
recognition of target cells at the site of in-
fection has only recently been under scru-
tiny. In abeautifully performedstudy, Egen34, May 27, 2011 ª2011 Elsevier Inc. 699
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Figure 1. Possible Mechanisms Underlying the Lack of Effector T Cell Arrest at Site
of Chronic Infections
Low antigen presentation as well as T cell-intrinsic defects may account for the paucity of long-lived inter-
actions between effector T cells and antigen-presenting cells at the site of infection.
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and effector functions of mycobacteria-
specific CD4+ T cells in liver granuloma
induced in mice by Bacille Calmette-
Gue´rin (BCG) or virulent Mycobacterium
tuberculosis.
In a first set of experiments, the authors
adoptively transferred preactivated p25
T cells (expressing a TCR specific for the
mycobacterial antigen Ag85b) and con-
trol nonspecific CD4+ T cells in mice pre-
viously infected with BCG and analyzed
their migration within liver granulomas
using intravital multiphoton imaging. Quite
surprisingly, the vast majority of both
mycobacteria-specific and nonspecific
T cells migrated vigorously. In fact, very
few specific T cells displayed the typical
hallmarks of antigen recognition, i.e.,
complete arrest or strong deceleration.
Yet, mycobacteria-specific T cells in the
liver were somehow seeing antigen, as
they had elevated surface expression of
the activation marker CD69. Because
this was seen as early as few hours after
T cell transfer, it is likely (although not
formally proven) that T cell receptor (TCR)
signaling occurred within the granuloma.
If so, one would have to assume that
TCR signals are received while T cells
are crawling within the granuloma, in the
absence of long-lived interactions with700 Immunity 34, May 27, 2011 ª2011 ElseviAPCs. It remained possible that the lack
of stable interactions established by
effector T cells reflected a bias introduced
by the use of T cells preactivated in vitro.
Therefore, the authors performed addi-
tional experiments transferring naive p25
T cells and leaving time for these cells to
be primed, expand, and home to the gran-
ulomas. But again, when examined under
the two-photon microscope, mycobacte-
ria-specific T cells were for the most part
not arrested.
These observations extend recent
imaging studies analyzing effector T cell
responses during chronic infections, in-
cluding Toxoplasma gondii in the brain
(Schaeffer et al., 2009), Leishmania major
in the skin (Filipe-Santos et al., 2009),
andLeishmaniadonovani in the liver (Beat-
tie et al., 2010). In all cases, antigen spec-
ificity only modestly altered effector T cell
behavior. One particularly original aspect
of the work by Egen et al. is the establish-
mentof a linkbetween the lackof p25Tcell
arrest and the low occurrence of IFN-g
production by these cells. At best, one
specific effector T cell out of fifteen was
actively producing this cytokine at any
given time point. Moreover, direct staining
of liver sections revealed only rare clusters
of IFN-g-producing CD4+ T cells. Whether
CD4+T cells specific for a different epitopeer Inc.or harboring a TCR of higher affinity would
exhibit a distinctbehavior in thegranuloma
microenvironment will be important to test
in future studies.
Altogether, these studies point to
a trend whereby the majority of activated
T cells may not engage in stable interac-
tions and cytokine production at effector
sites. What could explain this phenom-
enon? Several hypotheses could be put
forward. One obvious and likely one is
that chronic infections are associated
with limited antigen presentation, hence
restricting the number of APCs displaying
sufficient peptide-MHC complexes to
induce T cell arrest. This limitation could
originate from the variety of mechanisms
that pathogens have developed to inter-
fere with antigen presentation and lym-
phocyte activation. Alternatively, effector
T cells at the site of chronic infection
may repeatedly be encountering antigen
and become less sensitive to antigenic
stimulation over time. TCR downregula-
tion, TCR desensitization after activation,
or expression of inhibitory receptors (such
as PD-1) could limit T cell propensity to
arrest (Bikah et al., 2000; Fife et al.,
2009) (Figure 1). Egen et al. started to
address these possibilities by visualizing
that effector T cells were still capable of
immediate arrest when the cognate pep-
tide was injected intravenously. This indi-
cated that the machinery that triggers
T cell arrest was still functional in these
effector T cells. Nevertheless, subtle alter-
ations in T cell sensitivity to antigen might
not be revealed in the presence of such
a strong stimulus. Future studies exam-
ining the ability of chronically activated
T cell to arrest after TCR stimulation
should help resolve this issue. Finally,
intrinsic differences in the way that naive
and effector T cells behave upon antigen
recognition in vivo could also account
for the limited arrest of effector T cells.
Direct comparison of naive and activated
T cell behavior in response to systemic
peptide injection has revealed that naive
T cells are more prone to completely
arrest than their activated counterparts
(Azar et al., 2010). This might reflect differ-
ences in the way that T cells sense ‘‘stop’’
but also ‘‘go’’ signals provided by antigen
and the local chemokine microenviron-
ment, respectively (Dustin, 2004).
Whatever the mechanism, the observa-
tions made by Egen et al. have important
implications. This report, aswell as related
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Previewsstudies, confronts us with the complexity
of in vivo immune responses to infectious
agents and should substantially change
our perception of effector T cell activity.
Although textbooks traditionally repre-
sent this phase by an activated T cell
tightly binding to its target to execute
cytotoxic function or cytokine production,
the reality is much more complex, with
only a limited fraction of antigen-specific
T cells engaged in effector activity and
few of the infected cells and neighboring
cells being detected at any given time. In
the end, the net functional outcome of
the T cell response will be the integration
of these suboptimal processes over sev-
eral weeks, months, or years. Although
this represents a challenging task, it is
becoming obvious that this complexity
should now be incorporated into our way
of thinking about immunity to infection.
Additionally, this work raises several
intriguing questions. For example, is it
possible that T cells fulfill some of their
effector functions in vivo in the absence
of complete arrest and stable synapseformation? Are effector cytokines acting
uniquely on the cells that are targeted, or
does the effector response extend to
neighboring cells as a result of bystander
effects? Clearly, a better understanding
of the microanatomy of effector T cell
responses represents an important step
toward the rational design of vaccines
against chronic infections.
The report of Egen et al. offers in-
sights into what resembles an equilibrium
between a low yet detectable level of
effector T cell activity and the persistence
of an infectious agent. Future studies,
possibly using new imaging modalities to
track T cell effector functions in real time,
may help further clarify the significance
and the mechanism underlying subop-
timal effector T cell activity during chronic
infections.REFERENCES
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